Industry: Pharmaceuticals, Biotechnology
Xenova Group plc is a UK-based biopharmaceutical company focused on the development of novel drugs to treat cancer and addiction with a secondary focus in immunotherapy. The Group has a broad pipeline of products in clinical development, including three cancer programmes: its lead product TransMIDTM, for the treatment of high-grade glioma, now beginning Phase III trials, and the novel DNA targeting agents and XR303 both in Phase I for cancer indications. In addition to its cancer drugs, Xenova is developing two therapeutic vaccines for cocaine and nicotine addiction, in Phase II and Phase I trials respectively. In April 2001 Xenova acquired Cantab Pharmaceuticals plc and in September 2003 it acquired KS Biomedix Holdings ( www.xenova.co.uk )
Xenova Group plc
Cambridge Site 957 Buckingham Avenue
Slough, Berkshire SL1 4NL
United Kingdom
Tel: +44 1753 706600
Fax: +44 1753 706607
Instant Messenger: